Loading organizations...
§ Private Profile · Hauxton House, Mill SciTech Park, Mill Lane, Hauxton, Cambridge CB22 5HX, UK
Computational drug discovery company developing pre-clinical drug candidates using AI and quantum chemistry for pharma and biotech, focused on.
Kuano, based in London, UK, develops a computational platform integrating artificial intelligence, quantum chemistry, and molecular modeling to accelerate drug discovery and design, aiming to create and sell pre-clinical drug candidates. The platform focuses on rapid, cost-effective quantum modeling of enzymes to generate drug candidates for challenging diseases, which are then offered to pharmaceutical and biotech companies. The company has raised a total of £2.8 million in seed funding across two rounds, including £1 million in July 2021 and an additional £1.8 million in September 2023 to validate its quantum simulation platform. Key investors include ACF Investors and o2h Ventures, and Kuano has collaborated with institutions such as the UCL Drug Discovery Institute. Kuano was founded in 2020 by Vid Stojevic and David Wright.
Kuano has raised $3.0M across 2 funding rounds.
Kuano has raised $3.0M in total across 2 funding rounds.
Kuano has raised $3.0M in total across 2 funding rounds.
Kuano's investors include Robert Hornby, ACF Investors, Richard Lawrence Hargreaves, Ascension Ventures, Meltwind, o2h Ventures, Sunil Shah.
Kuano has raised $3.0M across 2 funding rounds. Most recently, it raised $2.0M Seed in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2023 | $2M Seed | Robert Hornby | ACF Investors, Richard Lawrence Hargreaves, Ascension Ventures, Meltwind, O2H Ventures | Announced |
| Jul 1, 2021 | $1M Seed | — | ACF Investors, Richard Lawrence Hargreaves, Sunil Shah | Announced |
Kuano is a Cambridge-based technology company developing a proprietary platform that integrates quantum computing, AI, and large-scale simulations to accelerate drug discovery.[1][2][3] The platform combines automated quantum mechanics (QM), molecular dynamics (MD), and quantum mechanics/molecular mechanics (QMMM) simulations with methods like FEP, MMPBSA, SAPT, FMO, DFT, and DMRG to explore drug-like chemical space rapidly.[1] It serves pharmaceutical companies and researchers tackling "undruggable" targets such as selectivity challenges, phosphatases, and metalloproteases, delivering solutions from hit identification (HitID) to lead optimization, including transition-state drug design.[1] Kuano's growth includes recent visibility at events like DiscoveryOnTarget in Boston (Oct 2025) and features in MedNous, signaling momentum in quantum-enhanced drug design.[3]
Kuano emerged as a startup in Cambridge, UK, focused on applying proprietary quantum algorithms to drug discovery and molecular simulation.[2] While specific founders are not detailed in available sources, the company positions itself as bringing cutting-edge quantum and AI expertise to the pharmaceutical industry, with a unique approach using machine learning and quantum physics to simulate, filter, and discover new molecules.[4][5] Early traction stems from its novel second-generation quantum computing techniques, supported by UKRI grants for innovation in drug discovery technologies.[5] Pivotal moments include platform development for real-world drug programs and recent 2025 engagements, such as discussions on quantum computation's future role in the field.[3]
Kuano rides the wave of quantum computing convergence with AI in drug discovery, where quantum simulations promise to model molecular interactions intractable for classical computers, speeding up processes from years to months.[1][2] Timing aligns with maturing quantum hardware and pharma's push for "undruggable" targets amid rising R&D costs and AI adoption; market forces like regulatory interest in computational tools and recent quantum milestones favor scalable platforms like Kuano's.[3] It influences the ecosystem by democratizing advanced simulations—via user-friendly interfaces—and fostering collaborations, as seen in 2025 conferences and publications, potentially lowering barriers for smaller biotechs entering quantum-aided design.[3][5]
Kuano is poised to expand its platform's adoption as quantum hardware scales and hybrid quantum-classical methods mature, targeting more lead optimizations and partnerships with big pharma. Trends like AI-physics hybrids and fault-tolerant quantum computing will amplify its edge, evolving its role from niche innovator to standard toolkit in drug design. Watch for deeper integrations with experimental validation pipelines, solidifying Kuano's lead in quantum-accelerated discovery.[1][3]